Literature DB >> 24744661

First Observation of MTH FR 678 C-A (Ala222Ala) Single Nucleotide Polymorphism.

Yonca Eğin1, Nejat Akar1.   

Abstract

Entities:  

Year:  2012        PMID: 24744661      PMCID: PMC3986968          DOI: 10.5152/tjh.2011.45

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

TO THE EDITOR

The enzyme methylenetetrahydrofolate reductase (MTHFR) plays a key role in folate metabolism. MTHFR catalyses NADPH-linked reduction of N5,10-methylenetetrahydrofolate to N5-methylene tetrahydrofolate. The MTHFR gene exhibits 2 common genetic polymorphisms (C677T and A1298C). The MTHFR 677 C to T substitution converts alanine to a valine residue, resulting in a thermolabile enzyme [1]. A reduction in MTHFR activity leads to an elevated plasma homocysteine level, which has been implicated as a risk factor for vascular and thromboembolic disease [2,3,4]. Real-time polymerase chain reaction (RT-PCR) facilitates quantification of polymorphic DNA regions and genotyping of single nucleotide polymorphisms (SNPs), including MTHFR C677T base substitution. The system is optimized to detect the difference in the Tm of the mutant and the wild-type allele using commercially available primers and hybridization probes [5]. Recently, MTHFR C685G (Iso225Val) and G679A (Asp223Asn) mutations other than the common MTHFR C677T were reported based on different melting points and RT-PCR [6], with an allele frequency of 1 in 3000-4000 samples [5]. A male patient’s DNA was isolated using a MagnaPure automatic isolation system (Roche Diagnostics, Indianapolis, USA). Genotyping of the MTHFR C677T polymorphism was performed via RT-PCR and fluorescence melting curve detection analysis using a LightCycler system (Roche Diagnostics, Manheim, Germany). Written informed consent was provided by the patient. The PCR product was purified using a Wizard SV PCR clean-up system (Promega, Madison, WI, USA), and sequenced using a CEQ Dye Terminator Cycle sequencing kit and a CSQ 8000 genetic analysis system (Beckman Coulter, Brea, CA, USA). Nucleotide changes were confirmed via a new PCR reaction, followed by sequencing analysis The patient had an unusual RT-PCR analysis melting point profile. The patient’s DNA was further analyzed via DNA sequencing, which showed a nucleotide change at 678 C>A that does not lead to an amino acid change (Ala- Ala). This polymorphism was not previously reported. Retrospectively, 4100 samples from our laboratory’s archives were analyzed, but none of these samples had an MTHFR 678C-A change. Research has shown that worldwide there is great variation in the prevalence of the MTHFR 677C-T mutation [2,7,8]. Several laboratory techniques are used to detect MTHFR C677T; the most common and reliable technique is melting point analysis, which can differentiate variants that lie within the region of the target probe. Differences in the base composition and nucleotide position affect Tm in wild-type and target mutations. Variants with Tm shifts of 2-5 °C are easily visualized during experiments, as was the case of MTHFR and other thrombophilia genes [5,9,10]. In the present study we reported a new heterozygous MTHFR gene polymorphism (678 C>A), with an unusual melting point profile. Although rare, the finding of MTHFR 678C>A polymorphism indicates that this might be technically important, as it may lead to erroneous reporting. Conflict of Interest Statement The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/ or affiliations relevant to the subject matter or materials included.
  10 in total

1.  Discovering rare variants by use of melting temperature shifts seen in melting curve analysis.

Authors:  Elaine Lyon
Journal:  Clin Chem       Date:  2005-08       Impact factor: 8.327

2.  Factor V null mutation affecting the Roche LightCycler factor V Leiden assay.

Authors:  Mani S Mahadevan; Paul V Benson
Journal:  Clin Chem       Date:  2005-08       Impact factor: 8.327

3.  Worldwide distribution of a common methylenetetrahydrofolate reductase mutation.

Authors:  J A Schneider; D C Rees; Y T Liu; J B Clegg
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

4.  Evaluation of electronic microarrays for genotyping factor V, factor II, and MTHFR.

Authors:  Maria Erali; Ben Schmidt; Elaine Lyon; Carl Wittwer
Journal:  Clin Chem       Date:  2003-05       Impact factor: 8.327

5.  Hyperhomocysteinemia: an independent risk factor for vascular disease.

Authors:  R Clarke; L Daly; K Robinson; E Naughten; S Cahalane; B Fowler; I Graham
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

6.  Prothrombin gene 20209 C >T along with the first description of a homozygous polymorphism at the 3' downstream region +4 C >T in the Turkish population.

Authors:  Hilal Ozdag; Yonca Egin; Nejat Akar
Journal:  Lab Hematol       Date:  2006

Review 7.  Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease.

Authors:  S C Guba; L M Fink; V Fonseca
Journal:  Am J Clin Pathol       Date:  1996-12       Impact factor: 2.493

8.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.

Authors:  P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

9.  The prevalence of methylenetetrahydrofolate reductase 677 C-T, factor V 1691 G-A, and prothrombin 20210 G-A mutations in healthy populations in Setif, Algeria.

Authors:  Romyla Bourouba; Bakhouche Houcher; Farida Djabi; Yonca Egin; Nejat Akar
Journal:  Clin Appl Thromb Hemost       Date:  2008-10-07       Impact factor: 2.389

10.  Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.

Authors:  G H Boers; A G Smals; F J Trijbels; B Fowler; J A Bakkeren; H C Schoonderwaldt; W J Kleijer; P W Kloppenborg
Journal:  N Engl J Med       Date:  1985-09-19       Impact factor: 91.245

  10 in total
  3 in total

1.  Is a high homocysteine level related to thrombosis?

Authors:  Sinasi Ozsoylu
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

2.  Thrombosis and risk factors: A comment.

Authors:  Selami Koçak Toprak; Yunus Kasım Terzi; Feride Sahin
Journal:  Turk J Haematol       Date:  2012-03-05       Impact factor: 1.831

3.  Thrombosis and risk factors: a comment.

Authors:  Nejat Akar
Journal:  Turk J Haematol       Date:  2012-03-05       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.